General
Preferred name
VILAZODONE
Synonyms
VILAZODONE HYDROCHLORIDE ()
Vilazodone D8 ()
SB659746A ()
EMD 68843 ()
Vilazodone HCl ()
EMD 68843 (Hydrochloride) ()
SB659746A (Hydrochloride) ()
Vilazodone (Hydrochloride) ()
EMD68843,SB659746A ()
EMD-68843, SB-659746A ()
Vilazodone (hydrochloride) ()
NGB 2904 (hydrochloride) ()
Vilazodone-d8 ()
Viibryd ()
SB-659746-A ()
EMD 68 843 ()
SB659746-A ()
EMD-68843 ()
EMD 515259 ()
EMD-515259 ()
EMD-68-843 ()
VIIBRYD ()
P&D ID
PD009553
CAS
163521-08-2
163521-12-8
189061-11-8
1794789-93-7
Tags
available
natural product
drug
Approved by
FDA
First approval
2011
Drug indication
Major depressive disorder
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Vilazodone's bioavailability is 72% when taken with food[Label,A38477].
ROE 1% of the dose is recovered unchanged in the urine and 2% of the dose is recovered unchanged in the feces[Label,A38477,A177628].
PHARMACODYNAMICS Vilazodone increases serotonin levels in the brain by inhibiting the reuptake of serotonin while acting as a partial agonist on serotonin-1A receptors[Label,A38477,A6947]. Due to this activity vilazodone has sometimes been referred to as a selective partial agonist and reuptake inhibitor (SPARI)[Label,A6947].
MOA Vilazodone selectively inhibits serotonin reuptake in the central nervous system as well as acting as a partial agonist of 5HT-1A receptors[Label,A38477]. The exact mechanism for how these effects translate to its antidepressant effects are not known[Label], though there is an association between these effects and antidepressive activity[A6947].
METABOLISM Vilazodone is mainly metabolized by cytochrome P450(CYP)3A4 and also to a minor extent by CYP2C19 and CYP 2D6[Label,A38477]. Although the metabolic pathway for vilazodone has not been fully studied, a proposed mechanism for metabolism in rats was published in 2017[A177622].;
INDICATION Vilazodone is approved for treatment of major depressive disorder[Label,A38477,A177622].
HALF-LIFE 25 hours[Label,A38477]. Other studies show a half life of 24±5.2h with a single 40mg dose and 28.9±3.2h with repeated doses[A177628].
DESCRIPTION Note that the USAN (United States Adopted Name) refers to the hydrochloride salt which has PubChem CID 6918313. (GtoPdb)
TOXICITY There is a lack of clinical studies of vilazodone in pregnancy[Label]. Animal studies have shown the effects on offspring to be reduced fetal weight, increased mortality, delayed maturation, and decreased fertility in adulthood at doses well above the maximum recommended human dose[Label]. Clinical cases of fetal and neonatal exposure to SSRIs and SNRIs have lead to a number of complications including respiratory distress, seizures, and temperature instability[Label]. It is not know whether vilazodone is excreted in the breast milk of nursing mothers but animal studies show this is the case for rats[Label]. The risk and benefit of breast feeding while taking vilazodone for mother and child must be considered before a decision is made[Label]. Safety and effectiveness in pediatric patients has not been established in clinical trials though antidepressants are associated with an increased risk of suicidal thought and behaviour in patients under 24 years[Label]. Clinical studies in geriatric patients showed to significant difference in response to vilazodone compared to younger patients[Label]. Geriatric patients should be started at a lower dose and titrated to an effective dose as they are more likely to have other comorbidities[Label]. Dosage adjustments are not necessary for patients of different genders or with reduced hepatic and renal function[Label].
DESCRIPTION Long-acting beta2 agonist (LABA) (Tocris Bioactive Compound Library)
DESCRIPTION Vilazodone is a serotonin 5-HT1A partial agonist and serotonin-selective reuptake inhibitor (SPARI) that is used clinically as an antidepressant for major depressive disorder. (BOC Sciences Bioactive Compounds)
Compound Sets
27
BOC Sciences Bioactive Compounds
vilazodone-hydrochloride-cas-163521-08-2-item-84-452540
Cayman Chemical Bioactives
21457
21547
25712
ChEMBL Approved Drugs
CHEMBL1615374
CHEMBL439849
ChEMBL Drugs
CHEMBL1615374
CHEMBL439849
Concise Guide to Pharmacology 2017/18
7427
Concise Guide to Pharmacology 2019/20
7427
Concise Guide to Pharmacology 2021/22
7427
Concise Guide to Pharmacology 2023/24
7427
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06684
DrugBank Approved Drugs
DB06684
DrugCentral
4223
DrugCentral Approved Drugs
4223
DrugMAP
DM4LECQ
DrugMAP Approved Drugs
DM4LECQ
EU-OPENSCREEN Bioactive Compound Library
EOS101268
EUbOPEN Chemogenomics Library
Guide to Pharmacology
7427
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL439849
MedChem Express Bioactive Compound Library
HY-14261
HY-14262
NCATS Inxight Approved Drugs
S239O2OOV3
ReFrame library
Selleckchem Bioactive Compound Library
vilazodone-hcl
vilazodone
TargetMol Bioactive Compound Library
T6232
T1279
The Spectrum Collection
Tocris Bioactive Compound Library
6202
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
441.22
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
4.03
TPSA
102.29
Fraction CSP3
0.31
Chiral centers
0.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Serotonin Transporter
5-HT Receptor
5-HT1A
SSRI
5-HT
Sert (Sodium-dependent)
DRD2, DRD3, HRH1, HTR1A, HTR4, SLC6A4
5-HT Receptor,Serotonin Transporter
Pathway
Neuronal Signaling
GPCR/G protein
Neuroscience
Primary Target
5-HT1A Receptors
MOA
Agonist
serotonin reuptake inhibitor
Indication
depression
Recommended Cell Concentration
None
Source data